Anti-4-1BB/4-1BBL
- 9 April 2017
- book chapter
- Published by Springer Nature
- p. 13-20
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Oncolytic Virus and Anti–4-1BB Combination Therapy Elicits Strong Antitumor Immunity against Established CancerCancer Research, 2012
- Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentBlood, 2011
- Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma ModelRadiation Research, 2010
- The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor SuperfamilyJournal of Biological Chemistry, 2010
- A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicityVaccine, 2009
- Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of MyelomaClinical Cancer Research, 2008
- Combination Therapy with Cisplatin and Anti–4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced NephrotoxicityCancer Research, 2008
- 4-1BB Costimulation of Effector T Cells for Adoptive Immunotherapy of Cancer: Involvement of Bcl Gene Family MembersJournal of Immunotherapy, 2007
- Serum levels of sCD137 (4‐1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non‐Hodgkin's lymphomaEuropean Journal of Haematology, 2006
- CD137 Expression in Tumor Vessel WallsAmerican Journal of Clinical Pathology, 2001